Protocol Ledger

NCT03881371 · Phase III · COMPLETED

A Study to Evaluate the Efficacy and Safety of Safinamide, as add-on Therapy, in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of Levodopa

Interventional Phase III clinical trial protocol NCT03881371 sponsored by Zambon SpA in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-08-01 Enrollment: 307 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03881371
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)307 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03881371
Protocol FieldVerified Registry Value
NCT IdentifierNCT03881371
Consolidated Lead SponsorZambon SpA
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment307 participants (ACTUAL)
Registered Start Date2019-08-01
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI